Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrit Jansen

Showing results (181-190 of 184) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 184 results.
Experimental Hematology & Oncology|January 12, 2013
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitorsSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Journal of the National Cancer Institute|May 28, 2010
Effect of noncompetitive proteasome inhibition on bortezomib resistanceXiaoming Li, Tabitha E Wood, Remco Sprangers, et al.
Oncotarget|October 27, 2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTORSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
British Journal of Cancer|June 5, 2020
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compoundsGiovanna Li Petri, Btissame El Hassouni, Rocco Sciarrillo, et al.
Pageof 19

Showing results (181-190 of 184) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 184 results.
Experimental Hematology & Oncology|January 12, 2013
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitorsSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Journal of the National Cancer Institute|May 28, 2010
Effect of noncompetitive proteasome inhibition on bortezomib resistanceXiaoming Li, Tabitha E Wood, Remco Sprangers, et al.
Oncotarget|October 27, 2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTORSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
British Journal of Cancer|June 5, 2020
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compoundsGiovanna Li Petri, Btissame El Hassouni, Rocco Sciarrillo, et al.
Pageof 19